The Medical Letter - 2019
Search or Select Article Below and Click to Purchase
Year:    Publication:     
March 25, 2019 (Issue 1568)  
March 11, 2019 (Issue 1567)  
February 25, 2019 (Issue 1566)  
February 11, 2019 (Issue 1565)  
January 28, 2019 (Issue 1564)  
  • OTC Primatene Mist Returns
    The FDA has approved over-the-counter (OTC) sale of inhaled epinephrine (Primatene Mist – Amphastar), a nonselective alpha and beta agonist, for temporary relief of mild symptoms of...
  • Qbrexza - A Glycopyrronium Cloth for Axillary Hyperhidrosis
    Qbrexza (Dermira), a premoistened cloth containing the long-acting anticholinergic drug glycopyrronium, has been approved by the FDA for once-daily topical treatment of excessive underarm...
  • Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation
    The FDA has approved Plenvu (Salix), a polyethylene glycol (PEG)-containing oral powder for reconstitution, for colon cleansing prior to colonoscopy in adults. Plenvu is the first...
  • Revefenacin (Yupelri) for COPD
    The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance...
  • Aripiprazole with Digital Ingestion Tracking (Abilify MyCite)
    Monitoring adherence of psychiatric patients to oral medication may be especially difficult. The FDA has approved Abilify MyCite (Otsuka/Proteus), an aripiprazole tablet with an embedded...
January 14, 2019 (Issue 1563)